(Q43280097)

18 November 2017

title

Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis (English)

1 reference

18 November 2017

Shai Yarkoni

1

1 reference

18 November 2017

Yuval Sagiv

2

1 reference

18 November 2017

Ayelet Kaminitz

3

1 reference

18 November 2017

Daniel L Farkas

4

1 reference

18 November 2017

Nadir Askenasy

5

1 reference

18 November 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

European Journal of Immunology

18 November 2017

published in

1 reference

18 November 2017

volume

39

1 reference

18 November 2017

issue

10

1 reference

18 November 2017

page(s)

2850-2864

1 reference

New concepts in the pathophysiology of inflammatory bowel disease

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

The immunology of mucosal models of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

T cell apoptosis and inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Critical role of caspases in the regulation of apoptosis and proliferation of mucosal T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Interleukin 2 signaling is required for CD4(+) regulatory T cell function

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Tolerance, not immunity, crucially depends on IL-2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Denileukin diftitox: a concise clinical review

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Regulatory T cells in the prevention of mucosal inflammatory diseases: patrolling the border

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Intestinal inflammation observed in IL-2R/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Control of intestinal inflammation by regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

CD4+CD25+ Regulatory T Cells Cure Murine Colitis: The Role of IL-10, TGF-β, and CTLA4

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Regulatory T cells and autoimmune disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

CD4+CD25+ T cells regulate colonic localization of CD4 T cells reactive to a microbial antigen.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Naturally arising CD4+CD25+ regulatory T cells suppress the expansion of colitogenic CD4+CD44highCD62L- effector memory T cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Control of regulatory T cell development by the transcription factor Foxp3

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+) -cell depleted, athymic and NK-cell depleted SCID mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Continuous generation of colitogenic CD4(+) T cells in persistent colitis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin‐2‐deficient colitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

CD4+ T cells, but not CD8+ T cells, are required for the development of experimental autoimmune gastritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

A synthetic mimetic of CD4 is able to suppress disease in a rodent model of immune colitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Homeostatic expansion of T cells during immune insufficiency generates autoimmunity.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

The dichotomous role of IL-2: tolerance versus immunity.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

The role of CD4+ CD25+ immunoregulatory T cells in the induction of autoimmune gastritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Regulatory T cell lineage specification by the forkhead transcription factor foxp3

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Caspase activation is required for T cell proliferation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Natural versus adaptive regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Mechanisms of T regulatory cell function

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Bcl-2 family members as sentinels of cellular integrity and role of mitochondrial intermembrane space proteins in apoptotic cell death

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200839190

7 January 2021

Identifiers

DOI

10.1002/EJI.200839190

1 reference

release_b5i2qdcms5bsxi5ovwulsgkwku

18 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b5i2qdcms5bsxi5ovwulsgkwku

24 November 2022

mapped directly with Wikidata item

1 reference